Farewell to Phenformin for Treating Diabetes Mellitus
- 1 October 1975
- journal article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 83 (4) , 567-568
- https://doi.org/10.7326/0003-4819-83-4-567
Abstract
Phenformin causes slight reduction of hyperglycemia, but controversy has existed concerning the mechanism. It may partially block absorption of glucose in the intestinal tract (1) and, under special circumstances, inhibits gluconeogenesis (2), but apparently these actions are relatively unimportant in the hypoglycemic action of phenformin in man. In in-vitro studies phenformin increased glucose uptake in isolated tissues in proportion to the amount of anaerobic glycolysis that it produced (3). The increased levels of plasma lactate in patients treated with this drug (4) suggests an increase in anaerobic metabolism. Phenformin has long been known to decrease insulin secretion (5). In viewKeywords
This publication has 7 references indexed in Scilit:
- THE INFLUENCE OF DIAGNOSTIC CRITERIA ON THE MORTALITY FINDINGS IN THE UNIVERSITY GROUP DIABETIC PROGRAMME STUDY OF DIABETIC THERAPYThe Medical Journal of Australia, 1973
- Effects of Hypoglycemic Agents on Vascular Complications in Patients With Adult-Onset DiabetesPublished by American Medical Association (AMA) ,1971
- Effects of Hypoglycemic Agents on Vascular Complications in Patients With Adult-Onset DiabetesJAMA, 1971
- Effect of Biguanides on Intestinal Absorption of GlucoseDiabetes, 1968
- Influence of Phenethylbiguanide on Lactic, Pyruvic and Citric Acids in Diabetic PatientsDiabetes, 1960
- Actions of Phenethylbiguanide and Related CompoundsDiabetes, 1959
- Respiratory inhibition and hypoglycemia by biguanides and decamethylenediguanidineBiochimica et Biophysica Acta, 1958